Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 196

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 196
---
:-------|-----------:|
| Preclinical to IND filing                                      |     | $      |     30,000 |
| From entering phase 1 to before first commercial sale          |     |        |  2,120,000 |
| First commercial sale                                          |     |        |  1,600,000 |
| Net sales amount more than certain threshold in a year         |     |        | 14,000,000 |
| Subtotal                                                       |     | $      | 17,750,000 |
| Diagnostics technology: up to the conditions and milestones of |     |        |            |
| Before FDA approval                                            |     | $      |    146,417 |
|                                                                |     | $      | 17,896,417 |

For the years ended December 31, 2024, 2023 and 2022, the Group incurred $61,123, $50,000 and $nil milestone payments under license agreements, respectively. For the years ended December 31, 2024, 2023 and 2022, the Group did not incur any royalties or research and development funding, respectively. C. Research and Development, Patents and Licenses, etc. As of the date hereof, the Company has 2 exclusively licensed technologies in the area of infectious diseases, and diagnostics. In addition, the Company is actively developing 1 proprietary technology. For the years ended December 31, 2024, 2023, and 2022, the Group incurred $2,195,161, $5,198,329, and $9,219,595, respectively, on research and development expenses. D. Trend Information Other than as disclosed elsewhere herein, we are not aware of any material recent trends in production, sales and inventory, the state of the order book and costs and selling prices since our last fiscal year. We are also unaware of any known trends, uncertainties, demands, commitments or events for the year ended December 31, 2024, that are reasonably likely to have a material adverse effect on our revenues, net income, profitability, liquidity or capital resources, or that would cause reported financial information not necessarily to be indicative of future operating results or financial conditions. E. Critical Accounting Estimates In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. However, uncertainty about these assumptions and estimates could